

MIMESIS

NEWSLETTER #1 / APRIL 2017

ENYO
PHARMA

A novel systems biology approach to develop preclinical assets from innovative drug discovery starting points inspired by viruses.

MIMESIS is a research and innovation project coordinated by ENYO Pharma and funded under the highly selective H2020 - SME Instrument - Phase 2 call that aims at: "Dedicated support to biotechnology SMEs closing the gap from lab to market". The MIMESIS project was launched on Nov 2016 for 2 years.

We will keep you updated regularly on the progress of the program.



This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement n° 739086-MIMESIS.


[Read more about mimesis](#)

After a successful feasibility phase for ENYO Pharma's approach, MIMESIS intends to execute the following scaled up plan:


- o Generate a small molecule library to identify modulators of a hundred human pathways known to be targeted by viruses.
- o Screen the library against disease relevant cell assays for infectious disease and expand the therapeutic focus to include non-infectious diseases.
- o From the output of cell based screens, prioritize targets and the molecule starting points for drug development.
- o Initiate the deployment of the approach for possible licensing to the pharmaceutical industry.

6 diseases with unmet clinical need will be addressed by MIMESIS:

- Infectious diseases
 - Influenza virus
 - Human rhinovirus
 - Respiratory syncytial virus
 - Zika virus
 - Mycobacterium tuberculosis
- Non infectious disease
 - Breast cancer



MIMESIS' Timeline



ABOUT ENYO PHARMA

ENYO Pharma is a biopharmaceutical company incorporated in January, 2014, by four scientists of the Infectiology Research Center in Lyon, France, and three seeding partners (2 privates and 1 public, Inserm Transfert Initiative). In February 2016, ENYO Pharma announced closing of a €22 million funding round led by Sofinnova Partners, alongside Morningside and Bpifrance via its fund InnoBio. This A-round financing has enabled ENYO Pharma to conduct Phase I trials for its lead molecule and phase II trials on chronic hepatitis B sufferers will follow in 2018.

Contact: Jacky Vonderscher, CEO / Eric Meldrum, CSO

mimesis@enyopharma.com

FOLLOW US ON: www.enyopharma.com



>> Click here to unsubscribe <<